Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 2 study titled A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome. The study aims to assess the effectiveness and safety of the drug HZN-1116 in treating Sjögren’s Syndrome, a chronic autoimmune condition. This research is significant as it targets both systemic disease activity and subjective symptoms in affected individuals.
The intervention being tested is HZN-1116, administered subcutaneously. It is designed to potentially alleviate symptoms of Sjögren’s Syndrome, offering a new therapeutic option for patients.
The study employs a randomized, parallel assignment model with quadruple masking, meaning neither participants nor researchers know who receives the drug or placebo. The primary goal is treatment-focused, ensuring unbiased results regarding the drug’s efficacy.
The study started on May 9, 2024, with primary completion expected by mid-2025. The last update was on August 20, 2025, indicating ongoing progress in the research.
This clinical update could positively influence Amgen’s stock, as successful results may lead to a new marketable treatment, boosting investor confidence. The study’s progress is crucial in a competitive industry where advancements in autoimmune disease treatments are highly valued.
The study is currently recruiting, with further details available on the ClinicalTrials portal.